Cases
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX)
Securities Class Action
Overview
Overview
- Date:
- 6/5/2018
- Company Name:
- MabVax Therapeutics Holdings, Inc.
- Stock Symbol:
- MBVX
- Class Period:
- FROM 3/14/2016 TO 5/18/2018
- Status:
- Closed/Complete
- Court:
- U.S. District Court: District of Southern California
NEW YORK, June 5, 2018 – Bragar Eagel & Squire, P.C. announces to investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX)
securities between March 14, 2016 and May 18, 2018 (the “Class Period”). Investors have until August 3, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose: (1) that the Company’s internal controls over financial reporting were materially weak and deficient; (2) that the Company had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or the Company’s officers and directors by certain shareholders; and, (3) that, as a result of the foregoing, the Company’s financial statements and Defendants' statements about MabVax’s business, operations, and prospects, were materially false and misleading at all relevant times.
If you purchased or otherwise acquired MabVax securities during the Class Period or continue to hold shares purchased during the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
securities between March 14, 2016 and May 18, 2018 (the “Class Period”). Investors have until August 3, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose: (1) that the Company’s internal controls over financial reporting were materially weak and deficient; (2) that the Company had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or the Company’s officers and directors by certain shareholders; and, (3) that, as a result of the foregoing, the Company’s financial statements and Defendants' statements about MabVax’s business, operations, and prospects, were materially false and misleading at all relevant times.
If you purchased or otherwise acquired MabVax securities during the Class Period or continue to hold shares purchased during the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.